Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and complications associated with COVID-19. Capricor is also investigating the field of exosomes and are exploring the potential of exosome-based candidates to treat or prevent a variety of disorders.
Location: United States, California, Los Angeles
Employees: 11-50
Phone: +1 310-358-3200
Total raised: $2M
Founded date: 2005
Investors 2
| Date | Name | Website |
| - | Mayo Clini... | ventures.m... |
| - | Johns Hopk... | ventures.j... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.12.2010 | - | $2M | - |
Mentions in press and media 17
| Date | Title | Description |
| 25.08.2026 | HHS plans new FDA deputy commissioner roles for technology and drugs, sources say | The Department of Health and Human Services is planning to appoint deputy commissioners for technology and drugs at the FDA, creating new roles at the agency, CNBC has learned. Like existing deputy commissioner roles, the two new positions ... |
| 30.07.2026 | FDA Panel Rejects Deramiocel Evidence as Lancet Validates Same Trial Data | By Alfredo Hanson Published: Jul 30 2026, 3:07 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 17.10.2024 | Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock | SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the pricing of its ... |
| 07.08.2024 | Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | -Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On Track to Report Top-Line... |
| 06.03.2024 | Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference | - |
| 08.02.2022 | Capricor Therapeutics Relocates to La Jolla | Things are clearly moving in the right direction for Capricor Therapeutics. In November, the company relocated its headquarters from Los Angeles to San Diego. And in last month, Capricor entered into a partnership with Japanese firm Nippon ... |
| 10.11.2021 | Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Form 8-K | Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update CAP-1002 - Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase... |
| 10.11.2021 | Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update | CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at the World Muscle Society Annual Meeting- -Me... |
| 24.09.2021 | Capricor Therapeutics : Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002 (Form 8-K) | Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002 -Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 ... |
| 24.09.2021 | Capricor Therapeutics : Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002 | –Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)– –Additional Positive Endpoints of Full PUL v2.0 (p=0.04) and Cardiac Endpoint of Ejection Fraction (p=0.002)– –One-Year Results Demonstrate... |
Show more